Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  West Pharmaceutical Services Inc.    WST

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Sales1 4211 4001 5091 6001 7321 874
EBITDA273280315338395431
Operating profit (EBIT)183190224242288334
Pre-Tax Profit (EBT)------
Net income12795,6144192221258
P/E ratio30,446,344,437,634,329,1
EPS ( $ )1,751,301,912,642,893,41
Dividend per Share ( $ )0,410,460,500,530,570,62
Yield0,77%0,76%0,59%0,53%0,57%0,62%
Reference price ( $ )53.2460.2284.8399.2299.2299.22
Announcement Date02/19/2015
12:00pm
02/18/2016
12:00pm
02/16/2017
12:17pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Debt--25,66,00--
Finance----58,074,0
Operating income (EBITDA)273280315338395431
Leverage
(Debt/EBITDA)
--0,08x0,02x--
Capital Expenditure-132170153158157
Book Value Per Share (BVPS)-14,2 $15,3 $17,7 $19,3 $21,6 $
Cash Flow per Share2,51 $2,88 $2,93 $4,11 $4,45 $4,85 $
Announcement Date02/19/2015
12:00pm
02/18/2016
12:00pm
02/16/2017
12:17pm
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2017e 2018e
Capitalization 7 367 M$ -
Entreprise Value (EV) 7 373 M$ 7 309 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 37,6x 34,3x
Capitalization / Revenue 4,60x 4,25x
EV / Revenue 4,61x 4,22x
EV / EBITDA 21,8x 18,5x
Yield (DPS / Price) 0,53% 0,57%
Price to book (Price / BVPS) 5,62x 5,13x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 15,2% 16,6%
operating Leverage (Delta EBIT / Delta Sales) 1,38x 2,28x
Net Margin (Net Profit / Revenue) 12,0% 12,8%
ROA (Net Profit / Asset) 10,1% 10,8%
ROE (Net Profit / Equities) 16,0% 15,2%
Rate of Dividend 20,1% 19,7%
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   9,57% 9,15%
Cash Flow / Sales 19,1% 19,1%
Capital Intensity (Assets / Sales) 1,19x 1,18x
Financial Leverage (Net Debt / EBITDA) 0,02x -0,15x
EPS & Dividend